Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis — Stella

Home/Dermatomyositis/

View on ClinicalTrials.gov

Recruiting

Back to Dermatomyositis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Cleveland Clinic, Cleveland, Ohio

Key details

Phase

Safety & dosing

Sponsor

The Cleveland Clinic

Enrollment target

~15 participants

Started

June 2025

Primary completion

December 2026

Age range

18 Years – 89 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.